α-葡萄糖苷酶抑制劑市場、機會、成長動力、產業趨勢分析與預測，2024-2032

全球 α-葡萄糖苷酶抑制劑市場價值為 33 億美元，預計 2024 年至 2032 年複合年成長率為 3.2%，受全球 2 型糖尿病盛行率激增的推動。

隨著全球人口老化和久坐生活方式的增加，糖尿病發生率不斷上升，尤其是在發展中國家。不斷擴大的患者群體增加了對有效治療的需求，例如α-葡萄糖苷酶抑制劑。這些抑制劑透過減緩腸道中碳水化合物的吸收來控制血糖，發揮至關重要的作用。此外，人們對早期糖尿病診斷和管理的認知不斷提高，加上政府和醫療機構採取的積極措施，正在推動市場的成長。

由於肥胖和不健康的生活方式等因素，全球對第 2 型糖尿病的關注日益增加，凸顯了對有效治療的需求。作為背景，國際糖尿病聯盟 (IDF) 在其 2022 年糖尿病圖譜中報告稱，約 5.37 億 20-79 歲成年人患有糖尿病，約佔該年齡層的 10.5%。預測顯示，到 2030 年，這一數字將增加至 6.43 億，到 2045 年將增至 7.83 億。

α-葡萄糖苷酶抑制劑產業依據藥物類型、適應症、類型、配銷通路和地區進行分類。

市面上將藥物類型分為阿卡波糖、米格列醇、伏格列波糖和複方藥物。阿卡波糖細分市場處於領先地位，到 2023 年將達到 15 億美元。阿卡波糖作為麥芽糖酶和蔗糖酶等酵素的競爭性抑制劑，可減緩碳水化合物的消化，導致餐後血糖適度上升。它在增強血糖控制方面的有效性，並且沒有顯著的體重增加或嚴重的低血糖，鞏固了其作為醫療保健專業人員青睞的選擇的地位。

α-葡萄糖苷酶抑制劑的通路包括醫院藥局、零售藥局和線上平台。 2023 年，醫院藥局處於領先地位，預計2024 年至2032 年複合年成長率為2.9%。情況下。通常，這些藥房是藥物的主要獲取點，特別是對於需要密切監測和調整劑量的複雜糖尿病患者。

2023年，北美α-葡萄糖苷酶抑制劑市場估值為14億美元，預計2024年至2032年複合年成長率為2.8%。率的上升2 型糖尿病和肥胖症。對糖尿病管理的認知的提高和先進的醫療設施加強了這種領導力。此外，主要製藥公司積極參與α-葡萄糖苷酶抑制劑的研發，推動了市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 2 型糖尿病盛行率上升
    • 擴大採用口服抗糖尿病藥物
    • 糖尿病管理意識不斷增強
  • 產業陷阱與挑戰
    • 不良副作用
    • 來自替代療法的競爭
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032 年

• 主要趨勢
• 阿卡波糖
• 米格列醇
• 伏格列波糖
• 組合藥物

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

• 主要趨勢
• 2型糖尿病
• 糖尿病前期

第 7 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 品牌化
• 通用的

第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Alkem Laboratories Ltd.
• Bayer AG
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Emcure Pharmaceuticals Ltd.
• Lupin Ltd.
• Merck and Co.
• Novartis AG
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company
• Torrent Pharmaceuticals Ltd.
• Unichem Laboratories Ltd.

The Global Alpha-Glucosidase Inhibitors Market was valued at USD 3.3 billion and is projected to grow at a 3.2% CAGR from 2024 to 2032, fueled by the surging global prevalence of type 2 diabetes.

With an aging global population and increasingly sedentary lifestyles, diabetes rates are climbing, especially in developing nations. This expanding patient demographic amplifies the demand for effective treatments, such as alpha-glucosidase inhibitors. These inhibitors play a crucial role in managing blood glucose by slowing carbohydrate absorption in the intestines. Furthermore, heightened awareness about early diabetes diagnosis and management, alongside proactive measures from governments and healthcare entities, is driving the market's growth.

The rising global concern over type 2 diabetes, spurred by factors like obesity and unhealthy lifestyles, underscores the demand for effective treatments. For context, the International Diabetes Federation (IDF) reported in its 2022 Diabetes Atlas that around 537 million adults aged 20-79 were living with diabetes, constituting roughly 10.5% of that age group. Projections suggest this number will escalate to 643 million by 2030 and 783 million by 2045.

The Alpha-Glucosidase Inhibitors Industry is classified based on drug type, indication, type, distribution channel and region.

The market categorizes drug types into acarbose, miglitol, voglibose, and combination drugs. Leading the pack, the acarbose segment accounted for USD 1.5 billion in 2023. Acarbose's dominant market position stems from its proven efficacy in type 2 diabetes management. Acting as a competitive inhibitor for enzymes like maltase and sucrase, acarbose slows carbohydrate digestion, resulting in a moderated rise in post-meal blood glucose. Its effectiveness in enhancing glycemic control, without significant weight gain or severe hypoglycemia, has cemented its status as a favored option among healthcare professionals.

Distribution channels for alpha-glucosidase inhibitors include hospital pharmacies, retail pharmacies, and online platforms. In 2023, hospital pharmacies took the lead, and are projected to grow at a CAGR of 2.9% from 2024 to 2032. Their dominance is attributed to their pivotal role in diabetes management, especially in inpatient scenarios where precise glucose control is paramount. Often, these pharmacies serve as the primary access point for medications, especially for patients with intricate diabetes cases necessitating close monitoring and dosage adjustments.

In 2023, the North American market for alpha-glucosidase inhibitors was valued at USD 1.4 billion, with projections indicating a growth rate of 2.8% CAGR from 2024 to 2032. North America's leading role in the alpha-glucosidase inhibitors market is due to rising rates of type 2 diabetes and obesity. Increased awareness about diabetes management and advanced healthcare facilities reinforce this leadership. Additionally, the proactive engagement of major pharmaceutical companies in researching and developing alpha-glucosidase inhibitors propels the market's growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of type 2 diabetes
    • 3.2.1.2 Growing adoption of oral antidiabetic drugs
    • 3.2.1.3 Growing awareness of diabetes management
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects
    • 3.2.2.2 Competition from alternative therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Acarbose
• 5.3 Miglitol
• 5.4 Voglibose
• 5.5 Combination drugs

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Type 2 diabetes mellitus
• 6.3 Pre-diabetes

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generic

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alkem Laboratories Ltd.
• 10.2 Bayer AG
• 10.3 Cipla Limited
• 10.4 Dr. Reddy's Laboratories Ltd.
• 10.5 Emcure Pharmaceuticals Ltd.
• 10.6 Lupin Ltd.
• 10.7 Merck and Co.
• 10.8 Novartis AG
• 10.9 Sanofi SA
• 10.10 Sun Pharmaceutical Industries Ltd.
• 10.11 Takeda Pharmaceutical Company
• 10.12 Torrent Pharmaceuticals Ltd.
• 10.13 Unichem Laboratories Ltd.